These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30851070)

  • 1. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
    Verma S; Bain SC; Monk Fries T; Mazer CD; Nauck MA; Pratley RE; Rasmussen S; Saevereid HA; Zinman B; Buse JB
    Diabetes Obes Metab; 2019 Jul; 21(7):1745-1751. PubMed ID: 30851070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
    Leiter LA; Bain SC; Bhatt DL; Buse JB; Mazer CD; Pratley RE; Rasmussen S; Ripa MS; Vrazic H; Verma S
    Diabetes Obes Metab; 2020 Sep; 22(9):1690-1695. PubMed ID: 32372454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
    Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
    Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
    Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
    Verma S; Bain SC; Honoré JB; F E Mann J; A Nauck M; E Pratley R; Rasmussen S; Sejersten Ripa M; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Nov; 22(11):2193-2198. PubMed ID: 32643857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
    Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
    JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
    Zinman B; Marso SP; Christiansen E; Calanna S; Rasmussen S; Buse JB;
    Diabetes Care; 2018 Aug; 41(8):1783-1791. PubMed ID: 29903847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP
    Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
    Shaman AM; Bain SC; Bakris GL; Buse JB; Idorn T; Mahaffey KW; Mann JFE; Nauck MA; Rasmussen S; Rossing P; Wolthers B; Zinman B; Perkovic V
    Circulation; 2022 Feb; 145(8):575-585. PubMed ID: 34903039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
    Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 May; 39(5):469-476. PubMed ID: 30887418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ
    Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.